ArticleGenes and immunity2010
Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.
Article in Genes and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.Arthritis research & therapy · 2019Trial
- Physical Activity Associates With Lower Systemic Inflammatory Gene Expression in Rheumatoid Arthritis.The Journal of rheumatology · 2022Observational
- New onset or exacerbation of uveitis with infliximab: paradoxical effects?BMJ open ophthalmology · 2019Article
- The clinical utility of gene expression examination in rheumatology.Mediterranean journal of rheumatology · 2017Review
- Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker.Frontiers in immunology · 2017Article
- Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?Frontiers in medicine · 2017Review
- The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes.Arthritis research & therapy · 2016Article
- Rheumatoid Arthritis: The Stride from Research to Clinical Practice.International journal of molecular sciences · 2016Review
- Is there a role of synovial biopsy in drug development?BMC musculoskeletal disorders · 2016Review
- Developing Peripheral Blood Gene Expression-Based Diagnostic Tests for Coronary Artery Disease: a Review.Journal of cardiovascular translational research · 2015Review
- Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Gene expression analysis in RA: towards personalized medicine.The pharmacogenomics journal · 2014Review
- Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.Genome medicine · 2013Article
- Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.PloS one · 2012Article
- Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?Nature reviews. Rheumatology · 2011Article
- Celastrus treatment modulates antigen-induced gene expression in lymphoid cells of arthritic rats.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To provide insight into the pharmacological changes in the peripheral blood (PB) molecular profile induced by tumor necrosis factor (TNF)-blockade in patients with rheumatoid arthritis (RA), blood was obtained in PAXgene tubes from 33 RA patients before and 1 month after TNF-blocking therapy (infliximab). From 15 randomly chosen patients pre- and post-treatment gene expression profiles were determined. The remaining 18 RA patients served as validation cohort. A group-based paired analysis of the gene expression profiles from the post- vs pre-treatment samples revealed a signature of genes significantly regulated by TNF-blockade. Downregulated genes reflected several biological pathways such as inflammation, angiogenesis, B- and T-cell activation. Further analysis revealed that the pharmacological response signature was significantly regulated in all treated patients, irrespective of clinical response, which is indicative for the presence of an active TNF pathway in all RA patients. The data imply that all patients carried features of TNF bioactivity irrespective of clinical response. These results favor a model for the parallel presence of TNF-dependent and TNF-independent pathways in the individual RA patient. Clinical response status to TNF-blockade may be dependent on the relative contribution of TNF-independent effector pathways.
Indexed as
Identifiers
20555356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.